How India Exports Tetracycline to the World

In the United States, tetracycline is an FDA-approved antibiotic available in various formulations. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for tetracycline, indicating a well-established generic market. As of March 2026, there are no active FDA import alerts specifically targeting tetracycline products from India, suggesting compliance with U.S. regulatory standards. However, importers must remain vigilant, as the FDA's Import Alert 36-04, updated on March 5, 2026, pertains to honey and blended syrup due to unsafe drug residues, including tetracycline. While this alert does not directly target pharmaceutical tetracycline, it underscores the FDA's stringent monitoring of antibiotic residues in imported products.

In the European Union, tetracycline is subject to the European Medicines Agency's (EMA) marketing authorization process. While specific data on tetracycline's approval dates are not readily available, the EMA has approved similar antibiotics, such as tigecycline (marketed as Tygacil), which received authorization on April 24, 2006. (ema.europa.eu) This indicates a structured regulatory pathway for antibiotics within the EU. Manufacturers exporting tetracycline to the EU must comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and regulation of pharmaceuticals, maintaining similar standards to the EMA.

Tetracycline is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The 23rd edition of the list, published in July 2023, features tetracycline, highlighting its continued relevance. (test-cms.who.int) This inclusion signifies that tetracycline is considered essential for addressing priority health needs worldwide. Additionally, tetracycline is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, tetracycline is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including tetracycline, to ensure affordability. As of the latest notification, the ceiling price for tetracycline has been set to maintain accessibility. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceuticals, ensuring compliance with national regulations.

Tetracycline's primary patents have long expired, leading to a robust generic market with significant competition. This has resulted in widespread availability and competitive pricing globally. The absence of active patents allows multiple manufacturers to produce and export tetracycline without infringement concerns.

In August 2025, the NPPA revised the ceiling price for tetracycline, reducing it by 5% to enhance affordability for patients. This adjustment reflects the authority's commitment to making essential medicines more accessible.

In November 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of tetracycline. This reaffirms the antibiotic's critical role in treating various bacterial infections globally.

In January 2026, the FDA issued Import Alert 36-04 concerning honey and blended syrup due to unsafe drug residues, including tetracycline. While this alert does not directly impact pharmaceutical tetracycline, it highlights the FDA's vigilance regarding antibiotic residues in imported products.

In February 2026, the EMA initiated a review of tetracycline-containing products to assess their benefit-risk balance, focusing on antimicrobial resistance concerns. This review aims to ensure the continued efficacy and safety of tetracycline in the European market.

In March 2026, the CDSCO issued new guidelines for the export of antibiotics, including tetracycline, emphasizing stringent quality control measures to align with international standards. These guidelines aim to bolster the credibility of Indian pharmaceutical exports.

These developments underscore the dynamic regulatory landscape surrounding tetracycline, reflecting ongoing efforts to balance accessibility, safety, and efficacy in the global pharmaceutical market.

India is a leading producer of Active Pharmaceutical Ingredients (APIs), including tetracycline. However, the country's pharmaceutical industry has historically depended on China for Key Starting Materials (KSMs) and intermediates essential for API synthesis. This reliance exposes the supply chain to risks associated with geopolitical tensions and trade disruptions. For instance, in June 2025, escalating conflicts in the Middle East led to the closure of the Strait of Hormuz, a critical maritime route for petrochemical feedstocks. This disruption affected the availability of raw materials necessary for pharmaceutical manufacturing, highlighting the vulnerability of supply chains dependent on specific geographic regions. (pharmasource.global)

To mitigate such dependencies, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic manufacturing of APIs and reduce reliance on imports. The scheme, launched in 2020, has seen multiple application rounds, with the latest opening in November 2025. This initiative encourages local production of critical APIs, including those for antibiotics like tetracycline, thereby enhancing supply chain resilience.

Our proprietary trade data indicates that the top five Indian exporters of tetracycline account for 49.1% of total exports, with LINCOLN PHARMACEUTICALS LTD leading at a 14.9% share. This concentration suggests a moderate risk of supply disruption if any of these key suppliers face operational challenges. The PLI scheme's focus on expanding domestic API production is expected to diversify the supplier base over time, potentially reducing single-source risks. However, as of March 2026, the full impact of these initiatives on supplier diversification remains to be seen.

Recent geopolitical events have significantly impacted global supply chains. In February 2026, the closure of the Strait of Hormuz due to military conflicts disrupted the transportation of essential raw materials, including those used in pharmaceutical manufacturing. This led to increased production costs and logistical challenges for Indian exporters. Additionally, tensions in the Red Sea region have further complicated shipping routes, causing delays and increased freight costs. (pharmasource.global) These disruptions have prompted regulatory bodies like the FDA to monitor potential drug shortages closely and collaborate with industry stakeholders to mitigate risks.

• Diversify Supplier Base: Encourage partnerships with multiple API and KSM suppliers across different regions to reduce dependency on any single source.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to invest in local manufacturing capabilities for critical raw materials.

• Strengthen Logistics Planning: Develop contingency plans for alternative shipping routes and modes of transportation to navigate geopolitical disruptions.

• Monitor Regulatory Developments: Stay informed about international regulatory alerts and collaborate with authorities to address potential shortages proactively.

• Implement Risk Assessment Protocols: Regularly evaluate supply chain vulnerabilities and establish protocols to respond swiftly to emerging risks.

RISK_LEVEL: MEDIUM